Exploring the Impact of Diabetes Medications on Dementia and Parkinson's Disease Risk

Thursday, 19 September 2024, 03:05

Diabetes medications might help reduce the odds for dementia and Parkinson's disease. Recent research indicates that SGLT2 inhibitors lower the risk of these neurodegenerative conditions. By working to filter sugar from the bloodstream, these drugs may also have protective benefits for brain health.
Healthday
Exploring the Impact of Diabetes Medications on Dementia and Parkinson's Disease Risk

Understanding the Connection Between Diabetes Medications and Neurological Health

A recent study revealed that a class of diabetes medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, commonly referred to as gliflozins, may play a role in safeguarding brain health by significantly reducing the risk of dementia and Parkinson's disease.

The findings suggest that SGLT2 inhibitors are linked to a 20% decrease in the risk of developing Alzheimer’s disease or Parkinson’s disease and a 30% reduction in the risk of vascular dementia.

Key Study Insights

The research analyzed nearly 359,000 individuals with type 2 diabetes who began treatment with diabetes medications between 2014 and 2019. Participants taking SGLT2 inhibitors displayed substantially lower rates of neurodegenerative diseases—Alzheimer’s cases were found to be under 40 per 10,000 person-years, compared to 64 for those using other medications.

  • Vascular dementia incidence was reported at nearly 11 cases per 10,000 person-years for SGLT2 users versus nearly 19 for others.
  • Parkinson's disease rates were slightly over 9 while others reported nearly 14.

Dr. Minyoung Lee from Yonsei University suggests that the outcomes hold steady even after accounting for various factors such as blood pressure and cholesterol. Despite the positive implications, he emphasizes the necessity for ongoing research to determine whether these drugs can offer long-term brain protection.

Implications for Diabetes Management

Individuals with diabetes should have a conversation with their healthcare providers about the potential benefits of SGLT2 inhibitors, considering their possible protective effects against dementia and Parkinson's disease.


Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the latest and most reliable health updates. Stay informed and enhance your wellness knowledge effortlessly.

Subscribe